International Clinical Trial: A single-arm, multicenter, prospective clinical study of Trastuzumab rezetecan combined with Adebrelimab and gemcitabine for the conversion treatment of biliary malignancies with HER2 mutations or overexpression

Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132885) titled 'A single-arm, multicenter, prospective clinical study of Trastuzumab rezetecan combined with Adebrelimab and gemcitabine for the conversion treatment of biliary malignancies with HER2 mutations or overexpression' on Sept. 20.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Zhongshan Hospital Affiliated to Xiamen University

Condition: Cholangiocarcinoma with HER2 mutation or overexpression

Intervention: Experimental group:Conversion treatment stage: Adalimumab, 1200 mg, intravenous infusion, on Day 1, every 21 days (Q3W) Trastuzumab emtansine, 4.8 mg/kg, if the patient's weight i...